Drug Discovery

06 May 2020
- Drug Discovery
- Research & Development
Lineage Cell Therapeutics to apply allogeneic dendritic cell therapy programme to Covid-19 vaccine development

By PBR Staff Writer

Lineage Cell Therapeutics, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced that it has applied for grant funding from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage’s allogeneic dendritic cell therapy, toward the development of a potential vaccine against SARS-CoV-2, the virus which causes COVID-19.
06 May 2020
Drug Discovery
Research & Development
Alexion to buy biopharmaceutical firm Portola in $1.41bn deal

By PBR Staff Writer

Alexion Pharmaceuticals has signed an agreement to acquire commercial-stage biopharmaceutical company Portola in a deal valued at around $1.41bn.
05 May 2020
Drug Discovery
Pre-clinical Studies
Vir, Alnylam to develop VIR-2703 RNAi therapeutic candidate for Covid-19 treatment

By PBR Staff Writer

Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
05 May 2020
Drug Discovery
Research & Development
Eli Lilly, Junshi collaborate to develop antibody therapies for Covid-19 disease

By PBR Staff Writer

Eli Lilly has collaborated with Junshi Biosciences for the development of therapeutic antibodies to treat and prevent Covid-19, the disease resulted due to the SARS-CoV-2 novel coronavirus.
04 May 2020
Drug Discovery
Research & Development
Canada grants AbCellera $124m for research on Covid-19

By PBR Staff Writer

AbCellera has secured a commitment of up to CAD175.6m ($124.3m) from the Government of Canada to discover solutions for Covid-19 and construct a manufacturing facility for antibody drugs.
01 May 2020
Drug Discovery
Research & Development
Moderna and Lonza announce worldwide strategic collaboration to manufacture Moderna’s vaccine against novel coronavirus

By PBR Staff Writer

Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and Lonza announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.
01 May 2020
Drug Discovery
Research & Development
Clinical Trials
Default Table Multi-Parameter Transmitter M800

By victoria.smith

The M800 multi-parameter transmitter provides simultaneous monitoring of one, two or four in-line sensors. It offers measurement of pH/ORP, optical DO, amperometric oxygen (DO as well as O2 gas), conductivity, resistivity, TOC, dissolved ozone, flow and turbidity in pure water as well as process applications.
29 Apr 2020
Drug Discovery
Research & Development
Quotient Sciences and CytoAgents accelerate potential treatment for COVID-19 cytokine storm

By PBR Staff Writer

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases.
28 Apr 2020
Drug Discovery
Research & Development
Merck and Institute for Systems Biology collaborate to define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers

By PBR Staff Writer

Merck, known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines.
28 Apr 2020
Drug Discovery
Research & Development
Affinia secures $1.6bn worth deal from Vertex to develop AAV capsids for genetic therapies

By PBR Staff Writer

Affinia Therapeutics has signed a research collaboration deal worth more than $1.6bn with Vertex Pharmaceuticals to discover and develop adeno-associated virus capsids (AAV capsids) to be used in the latter's genetic therapies aimed at treating people with serious diseases.

Drug Discovery

Research & Development

UCB to purchase Neurona and NRTX-1001 for $1.15bn

MSD secures EC approval for Enflonsia to prevent infant RSV infection

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Drug Discovery

Lineage Cell Therapeutics to apply allogeneic dendritic cell therapy programme to Covid-19 vaccine development

Alexion to buy biopharmaceutical firm Portola in $1.41bn deal

Vir, Alnylam to develop VIR-2703 RNAi therapeutic candidate for Covid-19 treatment

Eli Lilly, Junshi collaborate to develop antibody therapies for Covid-19 disease

Canada grants AbCellera $124m for research on Covid-19

Moderna and Lonza announce worldwide strategic collaboration to manufacture Moderna’s vaccine against novel coronavirus

Default Table Multi-Parameter Transmitter M800

Quotient Sciences and CytoAgents accelerate potential treatment for COVID-19 cytokine storm

Merck and Institute for Systems Biology collaborate to define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers

Affinia secures $1.6bn worth deal from Vertex to develop AAV capsids for genetic therapies

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found